pyrazines has been researched along with crizotinib in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, HM; Koudriakova, T; Romero, D; Skaptason, J; Tan, W; Vekich, S; Wilner, KD; Yamazaki, S | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Adam, A; Barry, ER; Beran, G; Cairo, S; Clark, EA; D'Cruz, CM; Déas, O; Fawell, SE; Frigault, MM; Hattersley, M; Henry, RE; Jones, RD; Linsenmayer, D; Nicolle, D; Reimer, C; Schuller, AG; Smith, A; Wilson, J; Zinda, M | 1 |
| Liu, H; Lu, S; Lu, T; Pan, J; Qiao, X; Xiang, B; Yan, L; Yuan, H; Zhang, L; Zhang, Y | 1 |
| Chen, KY; Fagin, JA; Ghossein, R; Knauf, JA; Luckett, KA; Socci, ND; Voza, F | 1 |
| Adeniran, A; Alva, A; Balzer-Haas, N; Bjarnason, GA; Cole, S; George, DJ; Heng, DYC; Humphrey, P; Lara, PN; Narayan, V; Pal, SK; Plets, M; Shuch, B; Stein, M; Tangen, C; Thompson, IM; Tretiakova, M; Vaishampayan, U; Wright, J; Zhang, T | 1 |
| Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N | 1 |
2 trial(s) available for pyrazines and crizotinib
| Article | Year |
|---|---|
Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Topics: Administration, Oral; Adult; Animals; Biological Availability; Cells, Cultured; Crizotinib; Dogs; Drug Evaluation, Preclinical; Half-Life; Hepatocytes; Humans; Macaca fascicularis; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Models, Molecular; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Triazoles; Young Adult | 2011 |
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Topics: Aged; Anilides; Canada; Carcinoma, Renal Cell; Crizotinib; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyridines; Sunitinib; Triazines; United States | 2021 |
5 other study(ies) available for pyrazines and crizotinib
| Article | Year |
|---|---|
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Cell Line, Tumor; Crizotinib; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Indoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyrroles; Sunitinib; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.
Topics: Binding Sites; Crizotinib; Humans; Hydrogen Bonding; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Mutation; Protein Binding; Protein Domains; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Triazoles; Tyrosine | 2018 |
Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Cell Line, Tumor; Coumarins; Crizotinib; Disease Models, Animal; Drug Resistance, Neoplasm; Genes, p53; Humans; Indoles; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mutation, Missense; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Pyrazines; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Triazoles | 2018 |
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |